Osteal Therapeutics Announces Positive Results from 12-Month Clinical Trial
Osteal Therapeutics, Inc., a clinical-stage biopharma company developing combination drug/device therapies for orthopedic infections, announced positive 12-month results from two clinical trials of VT-X7 KIT (vancomycin hydrochloride) for treating periprosthetic joint infections (PJI) of the hip or knee. The trials compared a rapid 7-day exchange arthroplasty with VT-X7 to the standard two-stage exchange approach in 152 patients across 23 U.S. centers. VT-X7 showed a 19% higher success rate (71% vs. 52%) and significantly reduced the median time to revision arthroplasty (7 days vs. 98 days). Patients treated with VT-X7 also had a shorter procedure time by 62 minutes and experienced a 71% lower overall PJI burden.
Osteal Therapeutics Announces Positive Results from 12-Month Clinical Trial